Back to Search
Start Over
Depot-Medroxyprogesterone Acetate Does Not Reduce the Prophylactic Efficacy of Emtricitabine and Tenofovir Disoproxil Fumarate in Macaques.
- Source :
-
JAIDS: Journal of Acquired Immune Deficiency Syndromes . 12/1/2014, Vol. 67 Issue 4, p365-369. 5p. - Publication Year :
- 2014
-
Abstract
- Concerns that the injectable contraceptive depot-medroxyprogesterone acetate (DMPA) may increase the risk of HIV acquisition in women led to questions on whether DMPA could reduce efficacy of pre-exposure prophylaxis (PrEP) for HIV prevention. We used a macaque model to investigate the impact of prolonged DMPA exposure on PrEP with emtricitabine/tenofovir disoproxil fumarate. Twelve pigtail macaques treated with DMPA were exposed vaginally to simian HIV once a week for up to 5 months and received either placebo (n = 6) or emtricitabine/tenofovir disoproxil fumarate (n = 6). All control macaques were infected, whereas the PrEP-treated animals remained protected (P = 0.0007). This model suggests that women using DMPA will fully benefit from PrEP. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 15254135
- Volume :
- 67
- Issue :
- 4
- Database :
- Academic Search Index
- Journal :
- JAIDS: Journal of Acquired Immune Deficiency Syndromes
- Publication Type :
- Academic Journal
- Accession number :
- 111805434
- Full Text :
- https://doi.org/10.1097/QAI.0000000000000340